Abstract:Background:As a key regulator of metabolic pathways, long non-coding RNA (lncRNA) has received much attention for its relationship with reprogrammed fatty acid metabolism (FAM). This study aimed to investigate the role of the FAM-related lncRNAs in the prognostic management of patients with lung adenocarcinoma (LUAD) using bioinformatics analysis techniques.Methods:We obtained LUAD-related transcriptomic data and clinical information from The Cancer Genome Atlas (TCGA) database. The lncRNA risk models associated with FMA were constructed by single-sample gene set enrichment analysis (ssGSEA), weighted gene co-expression network (WGCNA), differential expression analysis, overlap analysis, and Cox regression analysis. Kaplan-Meier (K-M) and receiver operating characteristic (ROC) curves were utilized to assess the predictive validity of the risk model. Gene set variation analysis (GSVA) revealed molecular mechanisms associated with the risk model. ssGSEA and microenvironment cell populations-counter (MCP-counter) demonstrated the immune landscape of LUAD patients. The relationships between lncRNAs, miRNAs, and mRNAs were predicted by using LncBase v.2 and miRTarBase. The lncRNA-miRNA-mRNA regulatory network was visualized with Cytoscape v3.4.0. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis was performed using DAVID v6.8. Quantitative real-time fluorescence PCR (qRT-PCR) was performed to verify the expression levels of the prognostic lncRNAs.Results:We identified 249 differentially expressed FMA-related lncRNAs in TCGA-LUAD, six of which were used to construct a risk model with appreciable predictive power. GSVA results suggested that the risk model may be involved in regulating fatty acid synthesis/metabolism, gene repair, and immune/inflammatory responses in the LUAD process. Immune landscape analysis demonstrated a lower abundance of immune cells in the high-risk group of patients associated with poor prognosis. Moreover, we predicted 279 competing endogenous RNA (ceRNA) mechanisms for 6 prognostic lncRNAs with 39 miRNAs and 201 mRNAs. Functional enrichment analysis indicated that the ceRNA network may be involved in the process of LUAD by participating in genomic transcription, influencing the cell cycle, and regulating tissue and organogenesis. In vitro experiments showed that prognostic lncRNA CTA-384D8.35, lncRNA RP5-1059L7.1, and lncRNA Z83851.4 were significantly upregulated in LUAD primary tumor tissues, while lncRNA RP11-401P9.4, lncRNA CTA-384D8.35, and lncRNA RP11-259K15.2 were expressed at higher levels in paraneoplastic tissues.Conclusion:In summary, the prognostic factors identified in this study can be used as potential biomarkers for clinical applications. ceRNA network construction provides a new vision for the study of LUAD pathogenesis.

Microarray Expression Profile of Long Non-Coding RNAs in Human Lung Adenocarcinoma.

Analysis of Microarray Data on Gene Expression and Methylation to Identify Long Non-coding RNAs in Non-small Cell Lung Cancer

Identification of Stage-associated MicroRNAs in Lung Adenocarcinoma Based on Microarray Data

Long Noncoding RNA Expression Profiles of Lung Adenocarcinoma Ascertained by Microarray Analysis

Expression profiles of long noncoding RNAs in lung adenocarcinoma.

Microarray Profiling of Differentially Expressed Lncrnas and Mrnas in Lung Adenocarcinomas and Bioinformatics Analysis

Genome-wide Analyses of Long Noncoding RNA Expression Profiles in Lung Adenocarcinoma

Genome-wide Analysis of Long Non-Coding RNA Expression Profile in Lung Adenocarcinoma Compared to Spinal Metastasis.

Detection of long-chain non-encoding RNA differential expression in non-small cell lung cancer by microarray analysis and preliminary verification.

Comprehensive Analyses of Molecular Features, Prognostic Values, and Regulatory Functionalities of M6a-Modified Long Non-Coding RNAs in Lung Adenocarcinoma.

Identification of Biomarkers for the Detection of Early Stage Lung Adenocarcinoma by Microarray Profiling of Long Noncoding RNAs.

Comparison of Dysregulated Long Noncoding RNAs in Lung Adenocarcinoma and Spinal Metastasis: A Genome-Wide Analysis.

Integrated Analysis of Long Non-Coding RNA-associated Cerna Network Reveals Potential Lncrna Biomarkers in Human Lung Adenocarcinoma

Microarray expression profile analysis of long non-coding RNAs in human gastric cardiac adenocarcinoma.

Prognostic Value of Lncrnas Related to Fatty Acid Metabolism in Lung Adenocarcinoma and Their Correlation with Tumor Microenvironment Based on Bioinformatics Analysis.

Differential expression and clinical significance of long non-coding RNAs in the development and progression of lung adenocarcinoma

Changes of long non-coding RNA expression profiling between pulmonary adenocarcinoma tissue and paracancerous tissue

The Long Noncoding RNA LINC01207 Promotes Proliferation of Lung Adenocarcinoma.

Systematic Identification of Cancer-Related Long Noncoding RNAs and Aberrant Alternative Splicing of Quintuple-Negative Lung Adenocarcinoma Through RNA-Seq

Identification of dysregulated long non-coding RNAs/microRNAs/mRNAs in TNM I stage lung adenocarcinoma.

LncRNAs Are Altered in Lung Squamous Cell Carcinoma and Lung Adenocarcinoma.